AwesomeStocks Hello! New Alert: BioSig Technologies, Inc. (NASDAQ: BSGM) BSGM is our brand new NASDAQ opportunity that has a history of experiencing significant upside. BSGM could present a breakout opportunity with a chart setup suggesting the potential for increased gains. In addition, BSGM announced multiple breaking developments recently that could be growth catalysts for the company. BSGM is an âadvanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmiasâ. Bioelectronic medicine is a new approach to treating and diagnosing disease and injury and BSGM could be on the frontlines of that change. This new field âuses device technology to read and modulate the electrical activity within the bodyâs nervous system, opening new doors to real-time diagnostics and treatment options for patientsâ. One of the exciting aspects of bioelectronic medicine is âits potential to supplement and even replace drugs, including their cost and often debilitating side effectsâ. As BSGM explains: âThrough collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcareâs biggest prioritiesâsaving time, saving costs, and saving lives.â The Companyâs âfirst product, the PURE EP⢠System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacyâ. âThe global EP market is projected to reach $16B in 2028 with an 11.2% growth rate.â âThe PURE EP⢠Platform is a unique combination of proprietary hardware and software that enables the real-time acquisition of raw signal dataâabsent of unnecessary noise or interferenceâallowing physicians to make informed clinical decisions based on clear and precise dataâ. âWith the heightened visualization of active signals, the PURE EP⢠Platform is facilitating personalized patient care and innovations in the field of electrophysiology.â Furthermore: âIn a blinded clinical study recently published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EP⢠as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating.â âThe PURE EP⢠Platform is currently in a national commercial launch and an integral part of well-respected healthcare systems, such as Cleveland Clinic, Mayo Clinic, Texas Cardiac Arrhythmia Institute, and Kansas City Heart Rhythm Institute.â BSGM has announced multiple accomplishments recently that could be significant growth catalysts for the company. Earlier this year the company announced: âBioSig Awarded US Patent Claims for its Universal Notch Filter Technologyâ Here are the highlights from this press release: - âPatent can remove any fixed frequency interfering with original signal of interest preserving critical intracardiac dataâ
- âBioSig now has 56 worldwide fundamental granted/allowed patents in the field of digital signal processingâ As the company further explained: âThis latest patent award further demonstrates our commitment to developing technology that protects elaborate cardiac signals and furthers the field of electrophysiology,â said Ken Londoner, Chairman, CEO and Founder of BioSig Technologies, Inc. âPURE EP⢠revitalizes the value of the EGM to help EPâs perform insight-based, highly targeted ablation procedures for even the most complex arrhythmias.â Furthermore: âBioSig now has 56 worldwide fundamental granted/allowed, 11 pending U.S. patent applications, and seven European/PCT applications covering its advanced signal processing technology. The company also has 13 pending patent applications in Asia including China, Korea, Japan and Taiwan.â In May, the company announced: âNew Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmiasâ Here are some of the highlights from this press release: - âData from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI)â
- âPreservation of raw unipolar signal using BioSigâs PURE EP⢠platform guidance enabled real-time tissue-specific feedback when conducting ablationâ In addition, the company also announced: âNew Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Marketâ As the company further explains: âThe PURE EP platform's proprietary hardware and software can dampen noise interference and pick up the unipolar signal clearly and in real-time with a level of precision that other platforms reportedly can't achieve.â Most recently, the company announced: âBioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcareâ Here are some of the highlights from this press release: âThe platformâs foundational machine learning model is anticipated to be based on integrated healthcare datasets, beginning with ECG and IECG data acquired by BioSigâs first product, the PURE EP⢠Platform. Electrophysiology-focused technological solutions developed under the terms of the collaboration may be integrated into PURE EP⢠technology for potential commercial application.â BSGM could be in a position to experience increased growth. Make sure to do your own due diligence. Sources: [Institute]( [PR1]( [PR2]( [PR3]( [PR4]( [PR5]( [PR6]( [PR7]( [PR8]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the âPublisherâ). The information (collectively the âAdvertisementâ) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the senderâs phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have not been compensated nor expect to receive any compensation for the distribution of information about BSGM dated 7/12/23. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 4/29/22 for the distribution of a prior advertisement about BSGM. Prior to 2022, at the time of publication, we disclosed our compensation for the distribution of advertisements about BSGM. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr
Orlando Florida 32822
USA [Unsubscribe]( | [Change Subscriber Options](